| Autor: |
Hiroshi Fujimaki, Akihiro Nakazawa, Motoharu Hirano, Tsuyoshi Takeuchi, Ayahiro Kadowaki, Yoshihiro Kusayama, Manabu Ide, Kenzo Kanai, Yoori Kim, Joji Matsubara, Ken Kumaga, Yutaka Inaba |
| Předmět: |
|
| Zdroj: |
Modern Rheumatology; Sep 2021, Vol. 31 Issue 5, p987-991, 5p |
| Abstrakt: |
Objectives: This study aimed to investigate the prevalence of patients with rheumatoid arthritis (RA) at a high risk of major osteoporosis (OP)-related fractures and the status of OP-related medical treatment for these patients. Methods: We enrolled 120 patients aged ≥40 years (average, 69.1 years) with RA. The Fracture Risk Assessment Tool (FRAXVR ) was used to evaluate the fracture risk. Of the 120 patients, the femoral neck bone mineral density (BMD) was evaluated in 102 patients, and their FRAXVR scores were calculated alongside the BMD values. Patients observed to be at a high risk of a major OP-related fracture (10-year probability >20% or hip fracture risk >3%), according to FRAXVR, were identified as those requiring OP treatment; medication ratio for OP (percentage of patients actually receiving medication among patients requiring OP treatment) was assessed. Results: OP treatment was indicated in 75 (63%) patients; the medication ratio for OP was 49%. The use of biological disease-modifying anti-rheumatic drugs and corticosteroids showed a positive effect; however, the use of methotrexate showed a negative effect on the medication ratio. Conclusion: The number of potential patients requiring OP treatment is underestimated. All patients with RA should be assessed to determine their eligibility for OP treatment. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
